Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLISOVI FE 1/20 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of heavy menstrual bleeding,Treatment of acne (off-label),Treatment of dysmenorrhea (off-label)
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4; desogestrel is a prodrug converted to etonogestrel, which is metabolized by CYP2C9 and CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: ~97-98% bound (primarily albumin); norethindrone: ~93-95% bound (primarily albumin and SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: ~2.5-4.0 L/kg; norethindrone: ~3.5-4.5 L/kg; large Vd indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); norethindrone ~50-70% (first-pass metabolism reduced with micronized formulation).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease; use contraindicated due to potential for fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment) due to reduced steroid clearance. Use with caution in Child-Pugh Class A; monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Use post-menarche. Standard dose: one tablet orally once daily for 21 days, then 7 days of placebo. Not indicated before menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dose adjustment; efficacy and safety not established in geriatric population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and number of cigarettes smoked, particularly in women over 35 years old.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of venous thromboembolism and arterial thrombosis,Increased risk of myocardial infarction and stroke, especially in smokers,Liver disease including hepatic adenoma and hepatocellular carcinoma,Hypertension,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache including migraine,Uterine bleeding irregularities,Depression,Hereditary angioedema,Chloasma,Ocular lesions (e.g., retinal thrombosis)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or history of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular or coronary artery disease,Known or suspected breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal uterine bleeding,Liver tumors or active liver disease,Migraine with aura if age ≥35,Diabetes with vascular involvement,Uncontrolled hypertension,Major surgery with prolonged immobilization,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. May be taken with or without food. Grapefruit juice may increase ethinyl estradiol levels but not clinically significant. Avoid St. John's wort (reduces efficacy). Alcohol consumption is not contraindicated but may increase side effects like nausea or dizziness.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Tri 1: No increased risk of birth defects in large cohort studies; however, combined hormonal contraceptives are contraindicated in pregnancy due to potential fetal harm from estrogen. Tri 2 & 3: No known teratogenicity; continuation after confirmed pregnancy not indicated.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norethindrone excreted in breast milk; no adverse effects reported. M/P ratio: Not available. Avoid use during breastfeeding if possible due to potential reduction in milk production.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated; discontinue if pregnancy occurs. No dose adjustment applicable in pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
BLISOVI FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg) with ferrous fumarate (75 mg) as an iron supplement in the placebo pills. The low estrogen dose may increase breakthrough bleeding risk, especially in the first few cycles. The ferrous fumarate tablets are not intended for contraceptive effect; ensure patients take active pills correctly. Missed pill management: if one active pill is missed, take as soon as remembered; if two or more active pills are missed, use backup contraception for 7 days and consider emergency contraception. Active pill color is pink; placebo pills are brown (ferrous fumarate). Contraindications: history of thromboembolic events, migraine with aura, liver disease, undiagnosed abnormal uterine bleeding, breast cancer, or pregnancy. Monitor for hypertension, depression, and cholestasis. Drug interactions: CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) reduce efficacy; antibiotics may also reduce efficacy (except rifampin-like drugs, which are definite).
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, preferably in the evening to reduce nausea.,The pill pack contains 21 active pink pills (hormonal) and 7 brown placebo pills (contain iron).,You will have a withdrawal bleed during the placebo week, typically starting 2-3 days after the last active pill.,If you miss a dose, refer to the package instructions: for one missed active pill, take it as soon as remembered; if more than one missed, use a backup method for 7 days.,Inform your healthcare provider if you experience severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,This medication does not protect against sexually transmitted infections; use condoms for prevention.,The iron in placebo pills may cause dark stools; this is harmless.,Store at room temperature away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BLISOVI FE 1/20 vs AFIRMELLE, answered by our medical review team.
BLISOVI FE 1/20 is a Oral Contraceptive that works by Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BLISOVI FE 1/20 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BLISOVI FE 1/20 is: One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BLISOVI FE 1/20 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BLISOVI FE 1/20 is classified as Category C. Tri 1: No increased risk of birth defects in large cohort studies; however, combined hormonal contraceptives are contraindicated in pregnancy due to potential fetal harm from estro. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.